Ticker > Company >

Valiant Laboratories share price

Valiant Laboratories Ltd.

NSE: VALIANTLAB BSE: 543998 SECTOR: Pharmaceuticals & Drugs  12.58 K   10   2

85.93
+1.52 (1.80%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 86.5

Today's Low

₹ 84.18

52 Week High

₹ 126.97

52 Week Low

₹ 70.41

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

466.71 Cr.

Enterprise Value

429.39 Cr.

No. of Shares

5.43 Cr.

P/E

694.66

P/B

1.47

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  58.49

CASH

96.72 Cr.

DEBT

59.4 Cr.

Promoter Holding

74.94 %

EPS (TTM)

₹  0.12

Sales Growth

-45.48%

ROE

0.2 %

ROCE

-0.3%

Profit Growth

-98.83 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-45.48%
3 YearNA
5 YearNA

Profit Growth

1 Year-98.83%
3 YearNA
5 YearNA

ROE%

1 Year0.2%
3 Year24.14%

ROCE %

1 Year-0.3%
3 Year19.2%

Debt/Equity

0.2508

Price to Cash Flow

9.57

Interest Cover Ratio

-8.6722

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 74.94 0.00
Mar 2025 74.94 0.00
Dec 2024 74.94 0.00
Sep 2024 74.94 0.00
Jun 2024 74.94 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 79.2339 days.
  • Company has a healthy liquidity position with current ratio of 7.9376.
  • The company has a high promoter holding of 74.94%.

 Limitations

  • The company has shown a poor profit growth of 0% for the Past 3 years.
  • The company has shown a poor revenue growth of 0% for the Past 3 years.
  • Company has low Interest coverage ratio of -8.6722.
  • The company has a low EBITDA margin of 0% over the past 5 years.
  • The company is trading at a high PE of 694.66.
  • The company is trading at a high EV/EBITDA of 124.6921.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 18.88 21.48 35.23 57.77 51.01
Total Expenditure 21.27 28.22 34.61 53.94 48.65
Operating Profit -2.39 -6.74 0.62 3.83 2.36
Other Income 2.17 1.93 0.67 0.65 0.67
Interest 0.05 0.01 0.06 0.06 0.07
Depreciation 0.5 0.51 0.51 0.51 0.51
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.77 -5.32 0.72 3.92 2.45
Tax 0.23 0.66 -0.88 0.69 0.63
Profit After Tax -1.01 -5.98 1.6 3.24 1.82
Adjusted EPS (Rs) -0.21 -1.28 0.34 0.69 0.39

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024
Net Sales 291.52 333.91 182.05
Total Expenditure 249.21 298.84 190.46
Operating Profit 42.32 35.07 -8.41
Other Income 1.95 4.89 9.68
Interest 0.07 0.25 0.08
Depreciation 2.49 1.56 1.95
Exceptional Items 0 0 0
Profit Before Tax 41.7 38.14 -0.75
Tax 14.21 9.14 -1.09
Net Profit 27.5 29 0.34
Adjusted EPS (Rs.) 7.84 8.27 0.07

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 16.28 32.56 43.45
Total Reserves 55.18 67.93 193.43
Borrowings 59.4 59.4 59.4
Other N/C liabilities 1.52 2.35 2.08
Current liabilities 49.43 50.52 26.36
Total Liabilities 181.81 212.76 324.73
Assets
Net Block 22.23 29.97 31.61
Capital WIP 1.45 0.05 0.22
Intangible WIP 0 0 0
Investments 0 0.01 80.97
Loans & Advances 1.34 0.77 2.66
Other N/C Assets 0 0 0
Current Assets 156.8 181.96 209.27
Total Assets 181.81 212.76 324.73
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024
Profit from operations 41.7 38.14 -0.75
Adjustment 3.07 1.82 2.03
Changes in Assets & Liabilities -28.05 -8.2 46.53
Tax Paid -14.47 -8.8 0.98
Operating Cash Flow 2.25 22.96 48.78
Investing Cash Flow -12.24 -21.18 -182.73
Financing Cash Flow 6.18 -1.53 135.8
Net Cash Flow -3.81 0.24 1.85

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 74.94 74.94 74.94 74.94 74.94
dhanvallabh ventures llp 46.84 46.84 46.84 46.84 46.84
kanchan shantilal vora 3.72 3.72 3.72 3.72 3.72
paresh shashikant shah 9.36 9.36 9.36 9.36 9.36
rachi santosh vora 0.02 0.02 0.02 0.02 0.02
santosh shantilal vora 7.50 7.50 7.50 7.50 7.50
shantilal shivji vora 7.50 7.50 7.50 7.50 7.50
varsha paresh shah 0.01 0.01 0.01 0.01 0.01
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 25.06 25.06 25.06 25.06 25.06
dhirajbhai vaghjibhai kor... - - - 1.16 1.12
l7 hitech private limited... 1.16 - - 2.23 1.17
llp 0.11 0.05 0.07 0.07 0.08
money logix securities pr... - - - 1.27 1.27
jainam broking limited 1.82 1.56 1.27 - -
priyanka shwetkumar korad... - 1.17 1.08 - -
niraj rajnikant shah 1.25 - - - -
vikasa india eif i fund -... 1.89 - - - -

Annual Reports

Title Link
Title Link
 No Annual reports exist for this company.Report us

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Valiant Laboratories - Quaterly Results 8 Aug, 4:49 PM Valiant Laboratories - Quaterly Results 8 Aug, 4:49 PM Valiant Laboratories - Quaterly Results 8 Aug, 4:49 PM Valiant Laboratories informs about credit rating 26 Jun, 4:50 PM Valiant Laboratories - Quaterly Results 20 May, 5:50 PM Valiant Laboratories - Quaterly Results 20 May, 5:50 PM Valiant Laboratories - Quaterly Results 20 May, 5:50 PM Valiant Laboratories informs about credit ratings 19 Feb, 3:17 PM Valiant Laboratories - Quaterly Results 7 Feb, 5:22 PM Valiant Laboratories - Quaterly Results 7 Feb, 5:22 PM Valiant Laboratories - Quaterly Results 7 Feb, 5:22 PM Valiant Laboratories informs about voting results of postal ballot 20 Dec, 5:10 PM Valiant Laboratories informs about credit rating 23 Aug, 4:57 PM Valiant Laboratories informs about newspaper publication 14 Aug, 5:02 PM Valiant Laboratories - Quaterly Results 12 Aug, 5:05 PM Valiant Laboratories - Quaterly Results 12 Aug, 5:05 PM Valiant Laboratories informs about disclosure 21 Jun, 5:16 PM Valiant Laboratories - Quaterly Results 14 May, 7:20 PM Valiant Laboratories - Quaterly Results 14 May, 7:20 PM Valiant Laboratories informs about newspaper publication 8 Mar, 4:32 PM Valiant Laboratories - Quaterly Results 9 Feb, 3:06 PM Valiant Laboratories - Quaterly Results 9 Feb, 3:06 PM Valiant Laboratories - Quaterly Results 9 Feb, 3:06 PM Valiant Laboratories - Quaterly Results 6 Nov, 6:41 PM Valiant Laboratories - Quaterly Results 6 Nov, 6:41 PM Valiant Laboratories coming with IPO to raise upto Rs 152.46 crore 26 Sep, 11:00 AM Valiant Laboratories files DRHP with SEBI 9 Jun, 11:57 AM

Valiant Laboratories Stock Price Analysis and Quick Research Report. Is Valiant Laboratories an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Valiant Laboratories. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Valiant Laboratories has a PE ratio of 690.379951495554 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Valiant Laboratories has ROA of 0.1266% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Valiant Laboratories has a Current ratio of 7.9376.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Valiant Laboratories has a ROE of 0.2017%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Valiant Laboratories has a Debt to Equity ratio of 0.2508 which means that the company has low proportion of debt in its capital.

  • Sales growth: Valiant Laboratories has reported revenue growth of -45.4785% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Valiant Laboratories for the current financial year is -4.61943923837314%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Valiant Laboratories is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Valiant Laboratories is Rs 0.1237. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Valiant Laboratories in Ticker for free. Also, one can get the intrinsic value of Valiant Laboratories by using Valuation Calculators, which are available with a Finology ONE subscription. 

Valiant Laboratories FAQs

Q1. What is Valiant Laboratories share price today?
Ans: The current share price of Valiant Laboratories is Rs 85.4.

Q2. What is the market capitalisation of Valiant Laboratories?
Ans: Valiant Laboratories has a market capitalisation of Rs 463.82875 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Valiant Laboratories?
Ans: The PE ratio of Valiant Laboratories is 690.379951495554 and the P/B ratio of Valiant Laboratories is 1.46010111285693, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Valiant Laboratories share?
Ans: The 52-week high share price of Valiant Laboratories is Rs 122.57713304721, and the 52-week low share price of Valiant Laboratories is Rs 69.8424034334764.

Q5. Does Valiant Laboratories pay dividends?
Ans: Currently, Valiant Laboratories does not pay dividends. Dividend yield of Valiant Laboratories is around 0%.

Q6. What are the face value and book value of Valiant Laboratories shares?
Ans: The face value of Valiant Laboratories shares is Rs 10, while the book value per share of Valiant Laboratories is around Rs 58.4891. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Valiant Laboratories?
Ans: Valiant Laboratories has a total debt of Rs 59.4002 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Valiant Laboratories?
Ans: The ROE of Valiant Laboratories is 0.2017% and ROCE of Valiant Laboratories is -0.2958%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Valiant Laboratories a good buy for the long term?
Ans: The Valiant Laboratories long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Valiant Laboratories undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Valiant Laboratories appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Valiant Laboratories’s financials?
Ans: You can review Valiant Laboratories’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Valiant Laboratories
X